DuPont Merck's Ethmozine (moricizine)
Executive Summary
Roberts Pharmaceuticals acquiring rights to the oral antiarrhythmic worldwide, excluding Japan. "The cardiac arrhythmia field no longer fits our core strategy," DuPont Merck said Dec. 18. Roberts plans to introduce the drug in the U.K. and France, where it has been approved, in 1993. Ethmozine received FDA approval for life- threatening ventricular arrhythmias in June 1990 and was introduced in the U.S. in September 1990.